{"entity":{"id":"nct02781883","kind":"trial","name":"Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML","aka":[],"tldr":"A phase 2 trial of Decitabine in acute myeloid leukaemia, run by Bio-Path Holdings, Inc., now recruiting.","summary":"Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML is a phase 2 interventional study registered as NCT02781883 by Bio-Path Holdings, Inc., with 108 participants planned, started 2016-05 and due to reach its primary completion in 2027-12. Interventions recorded: BP1001 in combination with Ventoclax plus decitabine and BP1001 plus decitabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02781883","url":"https://clinicaltrials.gov/study/NCT02781883"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["decitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02781883","phase":"2","setting":"A Phase IIa, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Venetoclax Plus Decitabine in Patients With AML Who Are Ineligible for Intensive Induction Therapy","sponsor":"Bio-Path Holdings, Inc.","enrolled":108,"outcomes":[]},"route":"/trials/nct02781883/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"decitabine","kind":"drug","name":"Decitabine","route":"/drugs/decitabine/"}]}}